Bivalirudin Reig Jofre for Percutaneous coronary intervention
Quick answer: Bivalirudin Reig Jofre is used for Percutaneous coronary intervention as part of a direct thrombin inhibitor (anticoagulant) treatment regimen. Direct, reversible inhibitor of thrombin (factor IIa) preventing fibrin formation and platelet activation The specific dosing for Percutaneous coronary intervention is determined by your prescriber based on individual factors.
Why is Bivalirudin Reig Jofre used for Percutaneous coronary intervention?
Bivalirudin Reig Jofre belongs to the Direct thrombin inhibitor (anticoagulant) class. Direct, reversible inhibitor of thrombin (factor IIa) preventing fibrin formation and platelet activation This action makes it useful for treating or managing Percutaneous coronary intervention in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Bivalirudin Reig Jofre is the right choice for a specific patient depends on the type and severity of Percutaneous coronary intervention, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Percutaneous coronary intervention
Common adult dosing range: 0.75 mg/kg IV bolus then 1.75 mg/kg/h infusion during PCI. The actual dose for Percutaneous coronary intervention depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Bivalirudin Reig Jofre medicine page.
What to expect
Bivalirudin Reig Jofre treatment for Percutaneous coronary intervention typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Percutaneous coronary intervention
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Bivalirudin Reig Jofre is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all Direct thrombin inhibitor (anticoagulant) for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Bivalirudin Reig Jofre
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Bivalirudin Reig Jofre full prescribing information · All Direct thrombin inhibitor (anticoagulant) alternatives
Frequently asked questions
How effective is Bivalirudin Reig Jofre for Percutaneous coronary intervention?
Effectiveness varies by individual response, dose, and severity. Bivalirudin Reig Jofre is one of several treatment options for Percutaneous coronary intervention, supported by clinical evidence within the direct thrombin inhibitor (anticoagulant) class. Discuss expected response with your prescriber.
How long do I need to take Bivalirudin Reig Jofre for Percutaneous coronary intervention?
Treatment duration depends on the nature of Percutaneous coronary intervention — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Bivalirudin Reig Jofre when used for Percutaneous coronary intervention?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Bivalirudin Reig Jofre for Percutaneous coronary intervention?
Yes. Multiple medicines and non-drug options exist for Percutaneous coronary intervention. Alternatives within the direct thrombin inhibitor (anticoagulant) class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.